|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma, Non-Hodgkin | |||||
| Lymphoma, T-Cell | |||||
| Lymphoma, T-Cell, Cutaneous | |||||
| Mycosis Fungoides | |||||
| Sezary Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| alefacept | |||||
| flow cytometry | |||||
| pharmacological study | |||||
| polymorphism analysis | |||||
| 5 | More general drug interventions related to this trial | ||||
| Dermatologic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Mayo Clinic | |||||
| National Cancer Institute (NCI) | |||||